Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
Explore this paper's citation graph
Summary
The aim of this article is to summarize concisely the current and rationally designed investigational therapeutics directed at JAK–STAT, hedgehog, PI3K–Akt, bone marrow fibrosis, telomerase, and rogue epigenetic signaling.
- Type
- article
- Published
- 2016-04-15
- Cited by
- 9
- References
- 169
- Access
- Open access
- OpenAlex
- https://openalex.org/W27143923
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13753636
Keywords
Medicine
References
- Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.
- Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
- Focus on the epigenome in the myeloproliferative neoplasms.
- A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
- Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.
- Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl
- Acquired DNA mutations associated with in vivo hydroxyurea exposure.
- Ruxolitinib For Patients With Primary Or Secondary Myelofibrosis before Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): A Retrospective Study Of The Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
- FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION
- Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis
- Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
- RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases
- Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
- Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
- Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC)
- Targeting the Pim kinases in multiple myeloma
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
- An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
Cited by
- An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T
- Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis
- The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
- Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
- Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics
- Assessing Symptom Burden in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Patients.
- Myelodysplastic and Myeloproliferative Neoplasms: Updates On The Overlap Syndromes
- Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+
- MYELODYSPLASTIC SYNDROMES ( D STEENSMA , SECTION EDITOR ) An Exercise in Extrapolation : Clinical Management of Atypical CML , MDS / MPN-Unclassifiable , and MDS / MPN-RST
Related papers
No related papers recorded.